An update on osteoarthritis therapeutics

M. Scott Hogenmiller, Carlos Lozada

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.

Original languageEnglish
Pages (from-to)256-260
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume18
Issue number3
DOIs
StatePublished - May 1 2006

Fingerprint

Osteoarthritis
Therapeutics
Intra-Articular Injections
Doxycycline
Cyclooxygenase 2 Inhibitors
Glucosamine
Hyaluronic Acid
Dietary Supplements
Disease Progression
Rheumatoid Arthritis
Adrenal Cortex Hormones
Research Personnel
Research

Keywords

  • Disease-modifying osteoarthritis drugs
  • Doxycycline
  • Glucosamine
  • Hyaluronic acid
  • Osteoarthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

An update on osteoarthritis therapeutics. / Hogenmiller, M. Scott; Lozada, Carlos.

In: Current Opinion in Rheumatology, Vol. 18, No. 3, 01.05.2006, p. 256-260.

Research output: Contribution to journalArticle

Hogenmiller, M. Scott ; Lozada, Carlos. / An update on osteoarthritis therapeutics. In: Current Opinion in Rheumatology. 2006 ; Vol. 18, No. 3. pp. 256-260.
@article{93ae0a600ae645ac80ceb1af3e61c527,
title = "An update on osteoarthritis therapeutics",
abstract = "Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.",
keywords = "Disease-modifying osteoarthritis drugs, Doxycycline, Glucosamine, Hyaluronic acid, Osteoarthritis",
author = "Hogenmiller, {M. Scott} and Carlos Lozada",
year = "2006",
month = "5",
day = "1",
doi = "10.1097/01.bor.0000218945.96988.0a",
language = "English",
volume = "18",
pages = "256--260",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - An update on osteoarthritis therapeutics

AU - Hogenmiller, M. Scott

AU - Lozada, Carlos

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.

AB - Purpose of review: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. Recent findings: The past year has led to a reassessment of the role of cyclooxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. Summary: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.

KW - Disease-modifying osteoarthritis drugs

KW - Doxycycline

KW - Glucosamine

KW - Hyaluronic acid

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=33646679608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646679608&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000218945.96988.0a

DO - 10.1097/01.bor.0000218945.96988.0a

M3 - Article

VL - 18

SP - 256

EP - 260

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -